Latest news with #Ultomiris
Cision Canada
07-08-2025
- Health
- Cision Canada
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG) Français
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) and adult patients with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (gMG). With the agreement in place with the pCPA, individual provinces and territories may now initiate the process to list Ultomiris on their formularies, the timing of which will vary by province and territory. NMOSD is a rare and debilitating autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves. 1-4 Most people living with NMOSD experience unpredictable relapses, characterised by a new onset of neurologic symptoms or worsening of existing neurologic symptoms, which tend to be severe and recurrent and may result in permanent disability. 4,5 gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness. 6 Those living with gMG may initially experience slurred speech, double vision, droopy eyelids and weakness, with symptoms becoming more severe as the disease progresses, including extreme fatigue, difficulty swallowing, choking and respiratory failure. 7-8 "NMOSD is a rare neurological disease characterized by severe relapses that have significant impact on patients' lives. In the pivotal trial for Ultomiris (ravulizumab), all Ultomiris -treated patients remained adjudicated relapse free at Week 72. This was achieved with a much-improved delivery regimen every 2 months compared to Soliris (eculizumab) that is dosed every 2 weeks. This agreement with the pCPA is a huge step forward to providing patients access to this treatment and improving treatment of NMOSD in Canada," said Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), The Ottawa Hospital. "Ensuring NMOSD patients have access to therapies proven highly effective is a top priority for The Sumaira Foundation globally. Since establishing TSF Canada in 2021, we have been supporting efforts to make these therapies available to Canadian patients as well. We are therefore very pleased to hear the news that ravulizumab is now becoming accessible to AQP4+ NMOSD patients in Canada. Congratulations to all stakeholders for their tireless efforts to make this possible, including the pan-Canadian Pharmaceutical Alliance (pCPA), Alexion Canada and of course, the patients and advocates who supported this important initiative," said Sumaira Ahmed, Executive Director and Founder, The Sumaira Foundation. "The recent pCPA decision marks a key milestone in access to ravulizumab, offering patients with generalized myasthenia gravis a targeted, evidence-based biologic therapy. This agreement advances the treatment landscape and reflects a commitment to improving outcomes and quality of life for those affected by this chronic neuromuscular disorder," said Hans Katzberg, MD, MSc, FRCPC, FAAN, Professor of Medicine, University of Toronto. "Reaching this agreement is an important milestone in addressing the treatment gap for individuals with generalized myasthenia gravis. We look forward to seeing public drug programs list Ultomiris quickly and equitably across the country. It's critical that our health systems reflect fairness and urgency in responding to the needs of those with rare diseases like MG," said Dr. Homira Osman, Vice President of Research & Public Policy, Muscular Dystrophy Canada. "We would like to thank the pCPA for its partnership in recognizing the need for this important innovation for Canadians living with NMOSD and gMG. We look forward to our ongoing collaboration with provincial and territorial jurisdictions to finalize listing agreements and secure public reimbursement for patients and their caregivers," said Karen Heim, Vice President and General Manager of Alexion Canada. NMOSD NMOSD is a rare disease in which the immune system is inappropriately activated to target healthy tissues and cells in the CNS. 1 Approximately three-quarters of people with NMOSD are anti-AQP4 Ab+, meaning they produce antibodies that bind to a specific protein, aquaporin-4 (AQP4). 2-4 This binding can inappropriately activate the complement system, which is part of the immune system and is essential to the body's defence against infection, to destroy cells in the optic nerve, spinal cord and brain. 2-4 It most commonly affects women and begins in the mid-30s. Men and children may also develop NMOSD, but it is even more rare. 9-12 People with NMOSD may experience vision problems, intense pain, loss of bladder/bowel function, abnormal skin sensations (e.g., tingling, prickling or sensitivity to heat/cold) and impact on coordination and/or movement. 5 Most people living with NMOSD experience unpredictable relapses, also known as attacks. Each relapse can result in cumulative disability including vision loss, paralysis and sometimes premature death. 4,5 NMOSD is a distinct disease from other CNS diseases, including multiple sclerosis. 13 The journey to diagnosis can be long, with the disease sometimes misdiagnosed. 1 gMG gMG is a rare autoimmune disorder characterised by loss of muscle function and severe muscle weakness. 6 Eighty-five percent of people with gMG are AChR antibody-positive meaning they produce specific antibodies (anti-AChR) that bind to signal receptors at the neuromuscular junction (NMJ), the connection point between nerve cells and the muscles they control. 14 This binding activates the complement system, causing the immune system to attack the NMJ leading to inflammation and a breakdown in communication between the brain and the muscles. 15 gMG can occur at any age, but it most commonly begins for women before the age of 40 and for men after the age of 60. 16 Initial symptoms may include slurred speech, double vision, droopy eyelids and lack of balance; these can often lead to more severe symptoms as the disease progresses such as impaired swallowing, choking, extreme fatigue and respiratory failure. 7,8 Ultomiris Ultomiris (ravulizumab), the longest-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Following a loading dose, Ultomiris is administered intravenously every eight weeks in adults, or every four or eight weeks in paediatric patients (based on body weight). Ultomiris is approved in the US, EU, Japan and other countries for the treatment of certain adults with paroxysmal nocturnal haemoglobinuria (PNH) and for certain children with PNH in the US and EU. Ultomiris is also approved in the US, EU, Japan and other countries for the treatment of certain adults and children with atypical haemolytic uraemic syndrome (aHUS). Additionally, Ultomiris is approved in the US, EU, Japan, China and other countries for the treatment of certain adults with generalised myasthenia gravis (gMG). Further, Ultomiris is approved in the US, EU, Japan and other countries for the treatment of certain adults with neuromyelitis optica spectrum disorder (NMOSD). Ultomiris is being assessed as a treatment for additional indications as part of a broad development programme. Alexion Alexion, AstraZeneca Rare Disease is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. For more information, please visit AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca. References Jarius S, et al. The History of Neuromyelitis Optica. J Neuroinflammation. 2013;10:8. Hamid SHM, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088-2094. Yick LW, et al. Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice. Front. Immunol. 2018;9:1438. Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. Mutch K, et al. Life on Hold: The Experience of Living with Neuromyelitis Optica. Disabil Rehabil. 2014:36(13):1100-1107. Jung-Plath W, et al. Assessment of myasthenia gravis patients' quality of life. The Journal of Neurological and Neurosurgical Nursing. 2023;12(2):74-83. Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus. 2019. Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology. 2020;3(2):48-54. Bukhari W, et al. Incidence and Prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017:88(8):632-638. Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489. Drori T, et al. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmunity Reviews. 2014;13(4-5):531–533. Eaneff S, et al. Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Multiple Sclerosis and Related Disorders. 2017;17:116–122. Mealy MA, et al. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. Int J MS care. 2019;21(3):129–134. Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981. Huang YF, et al. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve. 2024; 70(4):851-861. Cavanagh N, et al. Exploring the impairments and allied health professional utilization in people with myasthenia gravis: a cross-sectional study. J Clin Neurosci. 2023;114:9-16.
Yahoo
16-07-2025
- Business
- Yahoo
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others. Austin, TX, USA, July 16, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)), By End-use (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Ultomiris Drug Market size & share was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach a value of around USD 64.12 Billion by 2034, at a compound annual growth rate (CAGR) of about 31.52% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ Overview As per the industry experts at CMI, the global ultomiris drug market will witness a whopping CAGR between 2025 and 2034. This could be attributed to the rise in demand for various long-acting treatments for rare disorders, especially paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). North America holds the largest market share due to speedy adoption of ultomiris drug by the U.S. and Canada. Hospital pharmacies dominate as far as distribution channels are concerned. Key Trends & Drivers Long-Acting Treatment Preference to Spell Growth: Ultomiris does offer a long-acting dosing interval (every 8 weeks), which enhances patient convenience and compliance as compared to the shorter-acting alternatives. Ultomiris is also known for demonstrating robust clinical performance along with a well-established safety profile. Request a Customized Copy of the Ultomiris Drug Market Report @ Approval by Regulatory Bodies to Catalyze Growth: The U.S. FDA had approved ultomiris for adults suffering from gMG in the year 2022. Since then, the drug has strengthened its position in the neurology sector. The FDA also conducted a review on priority in March 2024 for ultomiris in NMOSD. These approvals and reviews are bound to take the ultomiris market to the next level in the forecast period. Report Scope Feature of the Report Details Market Size in 2025 USD 5.47 Billion Projected Market Size in 2034 USD 64.12 Billion Market Size in 2024 USD 4.16 Billion CAGR Growth Rate 31.52% CAGR Base Year 2024 Forecast Period 2025-2034 Prominent Players AstraZeneca, Xencor Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, Others, and Others Key Segment By Indication, End-use, Distribution Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Ultomiris Drug report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Ultomiris Drug report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Ultomiris Drug Market Report @ SWOT Analysis Strengths: Ultomiris has demonstrated a manageable safety profile and efficacy in the treatment of gMG and PNH. With the market for rare disease therapies growing on the whole, a favorable environment is created for ultomiris. Also, ongoing research coupled with clinical trials is bound to result in extra approved indications for ultomiris drug, thereby bolstering its market potential. Weaknesses: Ultomiris is quite expensive. This is likely to apply brakes to its accessibility for certain patients, particularly in the resource-limited settings. Moreover, the need for intravenous infusion could be a barrier to patient convenience and preference. Opportunities: Ultomiris has a huge potential for growth in the emerging markets with expansion of healthcare infrastructure and awareness regarding rare diseases. Furthermore, a subcutaneous formulation on the part of ultomiris is likely to offer a convenient route of administration for the patients. Also, exploration of the potential of combining ultomiris with the other therapies for improving treatment outcomes could fetch more revenue. Threats: There are pharmaceutical companies developing competing therapies for gMG and PNH, which is likely to erode the market share of ultomiris. Also, the development as well as the approval of ultomiris' biosimilar version is likely to adversely affect the market pricing and share. Request a Customized Copy of the Ultomiris Drug Market Report @ Key questions answered in this report: What is the size of the Ultomiris Drug market and what is its expected growth rate? What are the primary driving factors that push the Ultomiris Drug market forward? What are the Ultomiris Drug Industry's top companies? What are the different categories that the Ultomiris Drug Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Ultomiris Drug market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Ultomiris Drug Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The ultomiris drug market is classified into North America, Europe, Asia Pacific, and LAMEA. North America North America accounts for more than 40% of the market share, and the status quo is expected to remain unchanged during the forecast period. This could be credited to the U.S. being equipped with advanced diagnostic capabilities, which enable early detection as well as treatment of aHUS and PNH. Switching to ultomiris from soliris is witnessing acceleration, which is supported by the former's dosing intervals. Speedy adoption of innovative therapies and strong clinical trial activity are bolstering the market further. Higher level of awareness amongst the healthcare professionals regarding rare diseases ascertains timely intervention and diagnosis. Preference for therapies with a reduction in treatment burden does favor ultomiris over its counterparts. Asia Pacific The Asia Pacific is expected to expand at the fastest CAGR in the ultomiris market due to the rise in the number of patients with rare diseases. Improvement in healthcare infrastructure does improve access to advanced treatments through diagnosis. The structured approach toward rare disease management in Japan extends support to patient identification as well as treatment initiation. Integrating ultomiris into clinical practice does reflect the perceived benefits. Such elements do contribute to the presence of this drug in Japan. China's expanding healthcare system and emphasis on rare diseases do contribute to the growth of ultomiris market. Efforts in the direction of improving diagnostic capabilities facilitate detection of aHUS and PNH earlier. Moreover, increasing familiarity of healthcare professionals with complement inhibitors lends support to the adoption of the drug. Europe Europe's ultomiris market is strongly supported by growing awareness as well as diagnosis regarding rare diseases. Of late, ultomiris has been approved for pediatric use regarding conditions such as PNH. Clinical recommendations and guidelines do endorse the usage of ultomiris in the patient population. This transition to ultomiris from the existing therapies does reflect the perceived benefits. The region's emphasis on improvement of patient quality of life does support adopting treatments needing lesser hospital visits. LAMEA In LAMEA, physicians are increasingly recommending longer-acting treatment for reducing clinical visits and improving patient compliance. The educational efforts are improving understanding of complement-mediated cases across all the markets. Though regulatory timelines could vary, frequency of approvals is expanding across various countries. partnerships and collaborations in the healthcare sector contribute to the development of the market. Request a Customized Copy of the Ultomiris Drug Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)), By End-use (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Ultomiris Drug Market: AstraZeneca Xencor Inc. Chugai Pharmaceutical Argenx Alexion Pharmaceuticals Others Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Pet Oral Care Products Market: Pet Oral Care Products Market Size, Trends and Insights By Product Type (Toothbrush, Toothpaste, Mouthwash/Rinse, Dental Chews, Others), By Animal Type (Dogs, Cats, Others), By Application (Residential, Commercial), By Distribution Channel (Supermarkets and Hypermarkets, Online Stores, Specialized Pet Shops, Veterinary Channels), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Magnesium Supplements Market: Magnesium Supplements Market Size, Trends and Insights By Type (Tablets, Capsules, Powders, Liquids), By Application (Dietary Supplements, Pharmaceuticals, Animal Feed, Others), By Distribution Channel (Online, Offline), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Blockchain-Based Electronic Health Record Market: Blockchain-Based Electronic Health Record Market Size, Trends and Insights By Blockchain Type (Public Blockchain, Private Blockchain, Consortium/Permissioned Blockchain, Hybrid Blockchain), By Application (Patient Record Management, Clinical Trial Data Sharing, E-prescription & Medical Billing, Medical Imaging & Diagnostics, Insurance Claim & Fraud Detection, Remote Patient Monitoring (via IoMT)), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 AI in Synthetic Biology Market: AI in Synthetic Biology Market Size, Trends and Insights By Technology (Gene Synthesis, Genome Editing, Synthetic Biology Tools, Bioinformatics), By Application (Healthcare & Medicine, Agricultural Biotechnology, Industrial Biotechnology, Environmental Biotechnology), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Advanced Genomics Market: Advanced Genomics Market Size, Trends and Insights By Offering (Products, Services), By Technology (Sequencing, PCR, Gene Editing, Flow Cytometry, Microarrays, In Situ Hybridization), By Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture), By End-user (Hospitals and Clinics, Research Centers, Pharmaceutical and Biotechnology Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Cell and Gene Therapy Market: Cell and Gene Therapy Market Size, Trends and Insights By Therapy Type (Cell Theray, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, Others), By Delivery Method (In Vivo, Ex Vivo), By End-User (Hospitals, Cancer Care Centers, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Battery-Free Implants Market: Battery-Free Implants Market Size, Trends and Insights By Product Type (Neural Implants, Cardiac Implants , Cochlear Implants, Orthopedic Implants, Others), By Technology (Energy Harvesting, Wireless Power Transfer, RFID/NFC-based Systems), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutions, Specialty Clinics), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Alzheimer's Drug Market: Alzheimer's Drug Market Size, Trends and Insights By Type of Drug (Disease-Modifying Therapies (DMTs), Symptomatic Therapies), By Application (Amyloid-Targeting Agents, Tau-Targeting Agents, Cholinesterase Inhibitors, NMDA Antagonists, Other Agents), By End User (Hospitals, Clinics, Home Care Settings), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Ultomiris Drug Market is segmented as follows: By Indication Paroxysmal Nocturnal Hemoglobinuria (PNH) Atypical Hemolytic Uremic Syndrome (aHUS) Generalized Myasthenia Gravis (gMG) Neuromyelitis Optica Spectrum Disorder (NMOSD) By End-use Adult Pediatric By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Click Here to Get a Free Sample Report of the Global Ultomiris Drug Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Ultomiris Drug Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Ultomiris Drug Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Ultomiris Drug Market? What Was the Capacity, Production Value, Cost and PROFIT of the Ultomiris Drug Market? What Is the Current Market Status of the Ultomiris Drug Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Ultomiris Drug Market by Considering Applications and Types? What Are Projections of the Global Ultomiris Drug Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Ultomiris Drug Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Ultomiris Drug Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Ultomiris Drug Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Ultomiris Drug Industry? Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ Reasons to Purchase Ultomiris Drug Market Report Ultomiris Drug Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Ultomiris Drug Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Ultomiris Drug Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Ultomiris Drug Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Ultomiris Drug market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Ultomiris Drug Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Ultomiris Drug market analysis. The competitive environment of current and potential participants in the Ultomiris Drug market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Ultomiris Drug market should find this report useful. The research will be useful to all market participants in the Ultomiris Drug industry. Managers in the Ultomiris Drug sector are interested in publishing up-to-date and projected data about the worldwide Ultomiris Drug market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Ultomiris Drug products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Ultomiris Drug Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI offers a comprehensive solution that covers everything from data collection to investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts utilize client insights to inform strategies for estimating future declines, forecasting opportunities for growth, and conducting consumer surveys. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Ultomiris Drug Research Report | Fast Delivery Available - [220+ Pages] @
Yahoo
24-03-2025
- Business
- Yahoo
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year. Still, some companies are performing well amid the volatility. AstraZeneca (NASDAQ: AZN), a U.K.-based pharmaceutical giant, is one of them; its stock is up by an impressive 16% since January. This performance so far in 2025 is not a fluke. And the stock may deliver strong returns, if not in the next few weeks, but for investors willing to hold onto its shares for years. AstraZeneca's shares fell off a cliff late last year when it announced the arrest of some of its executives in China, including Leon Wang, the drugmaker's president in the country. That's on top of an insurance fraud investigation in China it had been dealing with, and allegations that the company imported illegal pharmaceutical drugs into the country. Though these problems are worth monitoring, AstraZeneca's financial results certainly aren't an issue. Last year, its revenue jumped by 18% year over year to $54.1 billion, an excellent performance for a pharmaceutical giant. Adjusted earnings per share were $8.21, 13% higher than the previous fiscal year. AstraZeneca operates several segments focused on various therapeutic areas, and every one except "other medicines" saw sales move in the right direction in 2024. Even with the challenges that AstraZeneca is dealing with now, last year's decline in its share price may have been overdone, given the company's strong financial results. That's likely why the stock has performed well since December, and has kept that momentum through market volatility this year. If it's found liable for illegal drug importation in China, AstraZeneca could incur a fine. The potential fine in China could amount to 100% to 500% of the unpaid importation taxes of $0.9 million. At worst, AstraZeneca will pay $4.5 million if it's found guilty -- a drop in the bucket for a company that generates tens of billions of dollars in annual revenue. The company will also face two patent cliffs in the U.S. this year. The first is for Soliris, a medicine for a rare blood disease called paroxysmal nocturnal hemoglobinuria. The second is for Brilinta, a treatment used to reduce the risk of heart attacks. Neither of these patent expirations should be a game changer for AstraZeneca. Soliris' sales in 2024 totaled $2.6 billion, but declined 18% year over year due to patients switching to AstraZeneca's newer Ultomiris. Brilinta's revenue in 2024 came in at $1.3 billion, up 1% year over year -- it was already facing generic competition in other countries. Because Soliris and Brilinta contributed little (if anything at all) to the pharmaceutical giant's top-line growth last year, the loss of exclusivity for these medicines won't harm its prospects. AstraZeneca has a lot to offer investors: a vast and diversified lineup of medicines, a deep pipeline, and steady revenue and earnings growth. Its lineup featured 14 medicines that each generated over $1 billion in sales last year. Yes, some will lose patent exclusivity, but others will fill the gap. Breztri, a treatment for chronic obstructive pulmonary disease (COPD), came short of blockbuster status for AstraZeneca last year with sales of $978 million, but they were up by 44% compared to 2023. Several other drugs should also continue to help drive strong top-line growth for the pharmaceutical leader, including the newer cancer therapy Truqap. Meanwhile, AstraZeneca's pipeline will likely unearth more gems. Like other drugmakers, it's now seeking to join the promising weight loss area. The company's investigational oral GLP-1 therapy, AZD5004, is undergoing phase 1 and 2 clinical trials across diabetes, weight management, and several other potential indications. (All currently approved GLP-1 medicines are administered subcutaneously, so there could be a reasonable demand for an oral option.) The company's AZD9550 is another potential GLP-1 medicine in early-stage studies. Beyond that, AstraZeneca is running many clinical trials across various therapeutic areas. The company had over a dozen regulatory approvals or clinical trial readouts in the fourth quarter. You can expect more of the same every period, which should allow its financial results to remain strong over the long run, even as it faces patent cliffs. Investors should see past the headwinds -- many already are, since the stock is performing well right now. But it's still time to think about purchasing shares of AstraZeneca. The drugmaker could deliver excellent returns. Before you buy stock in AstraZeneca Plc, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AstraZeneca Plc wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $721,394!* Now, it's worth noting Stock Advisor's total average return is 839% — a market-crushing outperformance compared to 164% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of March 18, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead was originally published by The Motley Fool Sign in to access your portfolio
